ArticleCNS neuroscience & therapeutics2020
High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.
Article in CNS neuroscience & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- An immune-related multi-omics analysis of dolichyl-diphosphooligosaccharide protein glycosyltransferase in glioma: Prognostic value exploration and competitive endogenous RNA network identification.IET systems biology · 2023Article
- Comprehensive analysis reveals COPB2 and RYK associated with tumor stages of larynx squamous cell carcinoma.BMC cancer · 2022Article
- Curzerene suppresses progression of human glioblastoma through inhibition of glutathione S-transferase A4.CNS neuroscience & therapeutics · 2022Article
- Article
- Characterization of Butyrate-Resistant Colorectal Cancer Cell Lines and the Cytotoxicity of Anticancer Drugs against These Cells.BioMed research international · 2022Article
- Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.CNS neuroscience & therapeutics · 2021Article
- Disruption of rack1 suppresses SHH-type medulloblastoma formation in mice.CNS neuroscience & therapeutics · 2021Article
- Silencing theExperimental and therapeutic medicine · 2021Article
- Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma.CNS neuroscience & therapeutics · 2021Article
- Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.CNS neuroscience & therapeutics · 2021Article
- Thrombospondin-1 is a prognostic biomarker and is correlated with tumor immune microenvironment in glioblastoma.Oncology letters · 2021Article
- COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC.BioMed research international · 2021Article
- High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.CNS neuroscience & therapeutics · 2020Article
- COPB2 gene silencing inhibits colorectal cancer cell proliferation and induces apoptosis via the JNK/c-Jun signaling pathway.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the clinical significance of coatomer protein complex subunit beta 2 (COPB2) in patients with glioma using a bioinformatics analysis.
methodsOncomine, GEO, and The Cancer Genome Atlas databases were used to examine the COPB2 transcript levels in glioma tissues. Gene expression profiles with clinical information from low-grade glioma and glioblastoma (GBM) projects were analyzed for associations between COPB2 expression and clinicopathologic characteristics. Kaplan-Meier survival and Cox regression analyses were used for survival analysis. Gene set enrichment analysis (GSEA) was conducted to screen the pathways involved in COPB2 expression. Gene set variation analysis (GSVA) and correlograms were performed to verify the correlations between COPB2 and inflammatory responses. Canonical correlation analyses examined whether COPB2-high patients have more infiltrating inflammatory and immune cells.
resultsCOPB2 was highly expressed in gliomas and high COPB2 expression correlated with shorter overall survival time and several poor clinical prognostic variables. GSEA indicated that some immune-related pathways and other signaling pathways in cancer were associated with the COPB2-high phenotype. The GSVA and canonical correlation analysis demonstrated that COPB2 expression was closely linked to inflammatory and immune responses, and higher immune cell infiltration.
conclusionsCOPB2 may be a potential prognostic biomarker and an immunotherapeutic target for glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.